Literature DB >> 18322825

[Neurological symptoms and disability in HTLV-1 associated myelopathy].

F J Carod-Artal1, H Mourao Mesquita, L da Silveira Ribeiro.   

Abstract

INTRODUCTION: The human T cell lymphotropic virus type I (HTLV-I) is a retrovirus that causes tropical spastic paraparesis/HTLV-I associated myelopathy (TSP/HAM). Objectives. To describe neurological characteristics and the severity of disability in a sample of patients with TSP/HAM.
METHODS: All TSP/HAM patients consecutively admitted during 2006 at the Brasilia Sarah Hospital, neurology outpatient clinic were included in the study. HTLV-I infected patient fulfilled criteria for serological positivity at both ELISA and western blot. Ashworth spasticity scale, Barthel index of activities of daily living, kurtzke functional systems and the Expanded Disability Status Scale (EDSS) were applied. All patients performed electrophysiological studies (evoked potentials, electromyogram) and brain/spinal cord magnetic resonance imaging (MRI).
RESULTS: Forty two of 249 paraparetic patients (16.9%; 26 females; mean age: 49.8 years) were diagnosed as having TSP/HAM. Mean time of evolution was 11.2 years. Most common neurological syndrome was a chronic progressive spastic paraparesis with hyperreflexia, ankle clonus and bilateral Babinski sign (97.7 %). Other findings were proximal muscle atrophy in lower limbs (28.6 %) , ataxia (21.4%), and peripheral neuropathy (7.1%). Half of patients were wheel-chair restricted or had a domiciliary walk. EDSS median was 6 and Barthel index mean score was 65. Most common findings on spinal cord MRI were thoracic spinal cord atrophy (66.7%) and white matter hyper-intensity areas in cerebral subcortical (42.8 %) and spinal cord (21.4%) regions.
CONCLUSIONS: TSP/HAM is a very disabilitating disorder. Peripheral neuropathy and ataxia are other syndromes that should be included in the spectrum of HTLV-I infection.

Entities:  

Mesh:

Year:  2008        PMID: 18322825

Source DB:  PubMed          Journal:  Neurologia        ISSN: 0213-4853            Impact factor:   3.109


  8 in total

Review 1.  Infectious diseases causing autonomic dysfunction.

Authors:  Francisco Javier Carod-Artal
Journal:  Clin Auton Res       Date:  2017-07-20       Impact factor: 5.625

2.  Early neurologic abnormalities associated with human T-cell lymphotropic virus type 1 infection in a cohort of Peruvian children.

Authors:  Emily A Kendall; Elsa González; Iván Espinoza; Martín Tipismana; Kristien Verdonck; Daniel Clark; Sten H Vermund; Eduardo Gotuzzo
Journal:  J Pediatr       Date:  2009-07-22       Impact factor: 4.406

3.  Atrophy, focal spinal cord lesions and alterations of diffusion tensor imaging (DTI) parameters in asymptomatic virus carriers and patients suffering from human T-lymphotrophic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP).

Authors:  Carlos Vilchez; Massiel Gonzalez-Reinoso; Caroline Cubbison; Eddy Perez-Then; Pedro Roa; Adriano Martínez; Bernd Foerster; Jairo Oviedo; Peter Stoeter
Journal:  J Neurovirol       Date:  2014-09-17       Impact factor: 2.643

4.  Living invisible: HTLV-1-infected persons and the lack of care in public health.

Authors:  Karina Franco Zihlmann; Augusta Thereza de Alvarenga; Jorge Casseb
Journal:  PLoS Negl Trop Dis       Date:  2012-06-12

5.  HTLV-1 and HTLV-2 Infection Among Warao Indigenous Refugees in the Brazilian Amazon: Challenges for Public Health in Times of Increasing Migration.

Authors:  Isabella Nogueira Abreu; Felipe Teixeira Lopes; Carlos Neandro Cordeiro Lima; Alexandre do Nascimento Barbosa; Lehi Rodrigues de Oliveira; Mayumi Aragão Fujishima; Felipe Bonfim Freitas; Mike Barbosa Dos Santos; Vitor Nina de Lima; Izaura M V Cayres-Vallinoto; Socorro Castelo-Branco; Hilton P da Silva; Antonio Carlos R Vallinoto
Journal:  Front Public Health       Date:  2022-02-11

6.  Is human T cell lymphotropic type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) syndrome a neglected disease?

Authors:  Jorge Casseb
Journal:  PLoS Negl Trop Dis       Date:  2009-11-24

7.  Severity score system for progressive myelopathy: development and validation of a new clinical scale.

Authors:  R M Castilhos; D Blank; C B O Netto; C F M Souza; L N T Fernandes; I V D Schwartz; R Giugliani; L B Jardim
Journal:  Braz J Med Biol Res       Date:  2012-05-10       Impact factor: 2.590

8.  Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder.

Authors:  Jose Abraão Carneiro Neto; Silvane Braga Santos; Gloria Orge Orge; Davi Tanajura; Lucia Passos; Cassius José Oliveira; Rosana Andrade; Cláudio Galeno de Melo; Ubirajara Barroso; Edgar M Carvalho
Journal:  Braz J Infect Dis       Date:  2018-02-17       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.